BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20054016)

  • 1. Re: International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.
    Köstler WJ; Brodowicz T; Zielinski CC;
    J Natl Cancer Inst; 2010 Feb; 102(3):207; author reply 207-8. PubMed ID: 20054016
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.
    Chlebowski RT
    J Natl Cancer Inst; 2010 Jan; 102(2):137. PubMed ID: 20019336
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of chemotherapy in metastatic breast cancer.
    Garber JE; Henderson IC
    Hematol Oncol Clin North Am; 1989 Dec; 3(4):807-21. PubMed ID: 2481671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized Trial.
    Ferretti G; Felici A; Carlini P; Cognetti F
    J Natl Cancer Inst; 2007 Sep; 99(18):1416. PubMed ID: 17848675
    [No Abstract]   [Full Text] [Related]  

  • 5. Dose density in breast cancer: a simple message?
    Lin NU; Gelman R; Winer EP
    J Natl Cancer Inst; 2005 Dec; 97(23):1712-4. PubMed ID: 16333021
    [No Abstract]   [Full Text] [Related]  

  • 6. Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy.
    Chlebowski RT; Irwin LE; Pugh RP; Sadoff L; Hestorff R; Wiener JM; Bateman JR
    Cancer Res; 1979 Nov; 39(11):4503-6. PubMed ID: 387216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
    Kröger N; Frick M; Gluz O; Mohrmann S; Metzner B; Jackisch C; Ko Y; Lindemann HW; Meier CR; Lohrmann HP; Ruffert U; Hänel M; Bodenstein H; Neubauer A; Ehninger G; Wolf HH; Kolbe K; Burock K; Zander AR; Nitz U
    J Clin Oncol; 2006 Aug; 24(24):3919-26. PubMed ID: 16921043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ixabepilone (Ixempra) for breast cancer.
    Med Lett Drugs Ther; 2008 Jan; 50(1278):7-8. PubMed ID: 18219261
    [No Abstract]   [Full Text] [Related]  

  • 9. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
    Holmes FA
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is it time for some new approaches for treating advanced ovarian cancer?
    McGuire WP
    J Natl Cancer Inst; 2006 Aug; 98(15):1024-6. PubMed ID: 16882933
    [No Abstract]   [Full Text] [Related]  

  • 13. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Doxorubicin and paclitaxel vs. 5-fluorouracyl, doxorubicin and cyclophosphamid in the first line treatment of metastatic breast cancer].
    Nagykálnai T
    Magy Onkol; 2002; 46(2):192-3. PubMed ID: 12202899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carboplatin in combination therapy for metastatic breast cancer.
    Perez EA
    Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
    Conte PF; Guarneri V; Bruzzi P; Prochilo T; Salvadori B; Bolognesi A; Aldrighetti D; Venturini M; Rosso R; Mammoliti S; Carnino F; Giannessi P; Costantini M; Moyano A; Baldini E;
    Cancer; 2004 Aug; 101(4):704-12. PubMed ID: 15305399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemotherapy in breast cancer -- the perils of history uncontrolled.
    Miller KD; Sledge GW
    Medscape Womens Health; 2000; 5(3):E1. PubMed ID: 11109042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel: new preparation. No first-line use in metastatic breast cancer.
    Prescrire Int; 2001 Dec; 10(56):178-9. PubMed ID: 11824441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer: metastatic.
    Johnston S; Stebbing J
    Clin Evid; 2002 Jun; (7):1579-602. PubMed ID: 12230774
    [No Abstract]   [Full Text] [Related]  

  • 20. Platinum-based chemotherapy in metastatic breast cancer: current status.
    Decatris MP; Sundar S; O'Byrne KJ
    Cancer Treat Rev; 2004 Feb; 30(1):53-81. PubMed ID: 14766126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.